Releases

October 14, 2020

Former NFL Players Show Interest in Regenerative Medicine and Cell Therapies

Mount Laurel, NJ – The National Football League Alumni Association (NFLA) today released a report exploring the interest in and use of regenerative medicine and cell therapies (RMCTs) for conditions of interest to NFLA members.

“We are thrilled about the tremendous response we received from our members for this survey,” said Kyle Richardson, board member and Co-Director of Healthcare Initiatives, NFL Alumni Association. “This report sends a clear message: Regenerative medicine is something that our members are interested in exploring, some have tried it, and many others are thinking about it but need more information about how and where to seek safe and effective therapies and treatments, especially for musculoskeletal conditions.”

As part of its “Care for Our Own” initiative, NFLA partnered with the Alliance for Cell Therapy Now (ACT Now) — an independent, non-profit collaboration of leaders representing academic and medical institutions, industry innovators, health care providers, and patients—and Sanford Health—one of the largest health systems in the United States and a member of ACT Now—to develop, conduct, and summarize the results of this survey. Read more

September 16, 2020

FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C)
First-of-its kind study to be supported by the Cura Foundation, The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now

New York, NY – The Cura Foundation in collaboration with The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now, is supporting a clinical trial of human cord tissue mesenchymal stromal cells (hCT-MSC) to treat children with Multisystem Inflammatory Syndrome in Children (MIS-C). The trial is being led by Dr. Joanne Kurtzberg at Duke University to determine if infusions of hCT-MSCs are safe and can suppress the hyper-inflammatory response and positively impact the symptom course and duration, as well as the long-term effects of this life-threatening syndrome. The hCT-MSCs are manufactured in the Robertson GMP Cell Manufacturing Laboratory at Duke. The U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) Application, and Dr. Kurtzberg will proceed with a multi-site pilot study later this month. Read more

June 3, 2020

MSC Therapy for Acute Respiratory Distress Syndrome; It’s Time to Accelerate Clinical Trials for COVID-19 Patients in Need

Washington, DC – A new systematic review and meta-analysis of clinical studies using mesenchymal stromal cells (MSCs) led by a team at the Mayo Clinic, and including researchers from Emory, Duke, Case-Western, and the University of Miami, shows a trend toward improved outcomes and reduced mortality for patients with acute respiratory distress syndrome (ARDS), a major complication for patients with COVID-19. This study—and several others—also have shown that MSCs are safe for patients. Based on these findings, the authors call for the rapid commencement of large-scale, confirmatory clinical trials to build on the existing evidence base, which shows a trend toward improved pulmonary function and reduced severe lung inflammation for patients with ARDS, paving the way toward another treatment option for seriously ill patients with COVID-19. Read more


January 27, 2020

Alliance for Cell Therapy Now and Bipartisan Policy Center Host Roundtable Discussion on Advancing Real-World Data and Evidence to Support Regulatory and Payment Decision-making for Regenerative Cell Therapies

Washington, DC – Today, the Alliance for Cell Therapy Now collaborated with the Bipartisan Policy Center to host a roundtable discussion on advancing the use of real-world data and evidence to support regulatory, payment, and patient decision-making for regenerative cell therapies. The event was co-chaired by former Food and Drug Administration (FDA) Commissioner and former Centers for Medicare and Medicaid Services (CMS) Mark McClellan and former FDA Commissioner and former National Cancer Institute (NCI) Director Andrew von Eschenbach. Read more


December 10, 2019

New Report Calls for Measurement of Outcomes and Federal Funding for Research and Increased Capacity at FDA to Advance Safe and Effective Regenerative Cell Therapies

Washington, DC – A new report released by the independent, non-profit Alliance for Cell Therapy Now, highlights the need for a national effort to measure outcomes related to regenerative cell therapies, as well as increased federal funding for research at the National Institutes for Health (NIH) and expanded capacity at the Food and Drug Administration (FDA) to support this rapidly growing field. The report is based on insights shared by several leaders during a September 2019 event on Capitol Hill hosted by Alliance for Cell Therapy Now in collaboration with the Regenerative Medicine Foundation and the Cord Blood Association. Read more


September 19, 2019

Alliance for Cell Therapy Now Hosts Briefing on Capitol Hill: Regenerative Cell Therapies: Making Safe and Effective Treatments Available to Patients

Washington, DC – Today, the Alliance for Cell Therapy Now hosted a briefing in Senate Hart Office Building on Capitol Hill to raise awareness of the actions needed to make safe and effective treatments available to patients in collaboration with the Regenerative Medicine Foundation and the Cord Blood Association. During the event, leaders from the Food and Drug Administration (FDA), the National Institutes of Health, and several academic and research institutions described the promise of regenerative cell therapies, as well as key imperatives for bringing both safe and effective treatments to patients in need. Read more